CGON CG Oncology, Inc. Common stock
USHealthcareAs of 2026-07-09 13:55
Why CGON matters now
CG Oncology, Inc. Common stock (CGON) is a US stock in Healthcare. The latest InvestLog snapshot shows $72.30 with +3.58% on the session and $6.38B in market capitalization; recent performance reads 1-month -3.51% and YTD +47.11%.
The latest financial table shown here is Q1 2026, with revenue of $1.1M, net income of $-60.2M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.0%.
The latest indexable market news headline is "CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $82.00; recent insider activity includes Mulay James filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.73
P/S
1062.40
EV/EBITDA
-29.06
DCF Value
$-3.39
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-664.8%
Operating Margin
-4239.0%
Net Margin
-3682.6%
ROE
-23.3%
ROA
-16.4%
ROIC
-19.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | $-60.2M | $-0.71 |
| Q4 2025 | $2.3M | $-41.3M | $-0.52 |
| FY 2025 | $4.0M | $-161.0M | $-2.08 |
| Q3 2025 | $1.7M | $-43.8M | $-0.57 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$82.57
Target (Median)
$82.00
Target Range
$70.00 - $93.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.31
CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a therapeutic option for patients suffering from high-risk Non-Muscle Invasive Bladder Cancer who have not responded to Bacillus Calmette Guerin (BCG) therapy, which represents the established standard of care for this particular severe form of NMIBC.